This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Addgene
product type :
cDNA
product name :
CMV566 empty vector
catalog :
33349
citations: 1
Reference |
---|
Rishi V, Gal J, Krylov D, Fridriksson J, Boysen M, Mandrup S, et al. SREBP-1 dimerization specificity maps to both the helix-loop-helix and leucine zipper domains: use of a dominant negative. J Biol Chem. 2004;279:11863-74 pubmed
|
product information
Catalog Number :
33349
Product Name :
CMV566 empty vector
article :
doi | 10.1074/jbc.M308000200 |
id | 4920 |
pubmed_id | 14702347 |
bacterial resistance :
Ampicillin
cloning :
backbone | pRc/CMV | |
backbone_mutation | ||
backbone_origin | 5500 | |
backbone_size | ||
promoter | CMV | |
sequencing_primer_3 | ||
sequencing_primer_5 | ||
vector_types |
|
growth notes :
(underlined bases are restriction sites for NcoI, NdeI, and HindIII) and 5 -CTAGAAGCTTCATCACATATGGGCATAATCGGGCACGTCGTAGGGATACGCCATGGTGG-3 (underlined bases are restriction site for XbaI).
-AGCTCCACCATGGCGTATCCCTACGACGTGCCCGATTA
TGCCCATATGTGATGAAGCTT-3
The polylinker region of the pRc/CMV eukaryotic expression vector (Invitrogen) was cut with NdeI and HindIII, and the following annealed oligonucleotide was inserted with a hemagglutinin epitope (YPYDVPDYASL) and NdeI-HindIII cloning site was made using the following pair of complementary oligonucleotides: 5
-AGCTCCACCATGGCGTATCCCTACGACGTGCCCGATTA
TGCCCATATGTGATGAAGCTT-3
The polylinker region of the pRc/CMV eukaryotic expression vector (Invitrogen) was cut with NdeI and HindIII, and the following annealed oligonucleotide was inserted with a hemagglutinin epitope (YPYDVPDYASL) and NdeI-HindIII cloning site was made using the following pair of complementary oligonucleotides: 5
origin :
37
resistance markers :
1114 |
tags :
High Copy
company information
Addgene
490 Arsenal Way, Suite 100
Watertown, MA 02472
Watertown, MA 02472
info@addgene.org
https://www.addgene.org617.225.9000
headquarters: USA
questions and comments